DHODH and glioblastoma: EVs modified with Angiopep-2 peptides are loaded with iron nanoparticles, glutathione peroxidase 4 and dihydroorotic dehydrogenase inhibitors to target glioblastoma by local magnetic localization and lipoprotein receptor protein 1 recognition.